Cargando…

Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy

PURPOSE: Patients with hypercortisolism have been associated with a higher prevalence of the pachychoroid spectrum including central serous chorioretinopathy (CSCR), which may explain the inconsistency of therapeutic responses of the mineralocorticoid receptor antagonist because hyperaldosteronism h...

Descripción completa

Detalles Bibliográficos
Autores principales: Chantarasorn, Yodpong, Rasmidatta, Kochapong, Pokawattana, Itsara, Silpa-archa, Sukhum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192783/
https://www.ncbi.nlm.nih.gov/pubmed/35711967
http://dx.doi.org/10.2147/OPTH.S368427
_version_ 1784726319129427968
author Chantarasorn, Yodpong
Rasmidatta, Kochapong
Pokawattana, Itsara
Silpa-archa, Sukhum
author_facet Chantarasorn, Yodpong
Rasmidatta, Kochapong
Pokawattana, Itsara
Silpa-archa, Sukhum
author_sort Chantarasorn, Yodpong
collection PubMed
description PURPOSE: Patients with hypercortisolism have been associated with a higher prevalence of the pachychoroid spectrum including central serous chorioretinopathy (CSCR), which may explain the inconsistency of therapeutic responses of the mineralocorticoid receptor antagonist because hyperaldosteronism has rarely been detected in patients with CSCR. Therefore, this study aimed to evaluate the effects of ketoconazole, the first-line cortisol inhibitor, on the resolution of subretinal fluid (SRF) in CSCR and to analyze correlations between choroidal thickness and steroid hormones. PATIENTS AND METHODS: This retrospective cohort study included 41 naïve CSCR eyes of 41 patients categorized into control (20 eyes) and treatment (21 eyes) groups. Patients in the treatment group were administered oral ketoconazole at a daily dose of 400 or 600 mg for 3–6 weeks. At week 12, rescue laser therapy was applied to patients exhibiting persistent SRF. Thus, a survival analysis was performed to determine the time interval from presentation to clinical resolution of SRF. Secondary outcomes consisted of eyes with persistent SRF and factors affecting the therapeutic response. RESULTS: The mean 24-hour urinary free cortisol (UFC) levels were elevated at 181 ± 70 and 150 ± 68 µg/day (range: 20–150) in the treatment and control groups, respectively (p = 0.21). After controlling for age and gender, baseline UFC levels were significantly associated with choroidal thickness in both eyes (p < 0.05). Ketoconazole significantly increased the CSCR resolution with the median time to resolution of 7 vs 16 weeks (p < 0.01) and decreased the proportion of eyes receiving rescue therapy at 12 weeks (23.8% vs 50%; p = 0.01). Prolonged CSCR durations were likely found in elderly patients with thick choroids in fellow eyes. CONCLUSION: Patients with CSCR showed elevated glucocorticoids, which further correlated with their choroidal thickness. Using cortisol blockers may shorten the duration of existing SRF.
format Online
Article
Text
id pubmed-9192783
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-91927832022-06-15 Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy Chantarasorn, Yodpong Rasmidatta, Kochapong Pokawattana, Itsara Silpa-archa, Sukhum Clin Ophthalmol Original Research PURPOSE: Patients with hypercortisolism have been associated with a higher prevalence of the pachychoroid spectrum including central serous chorioretinopathy (CSCR), which may explain the inconsistency of therapeutic responses of the mineralocorticoid receptor antagonist because hyperaldosteronism has rarely been detected in patients with CSCR. Therefore, this study aimed to evaluate the effects of ketoconazole, the first-line cortisol inhibitor, on the resolution of subretinal fluid (SRF) in CSCR and to analyze correlations between choroidal thickness and steroid hormones. PATIENTS AND METHODS: This retrospective cohort study included 41 naïve CSCR eyes of 41 patients categorized into control (20 eyes) and treatment (21 eyes) groups. Patients in the treatment group were administered oral ketoconazole at a daily dose of 400 or 600 mg for 3–6 weeks. At week 12, rescue laser therapy was applied to patients exhibiting persistent SRF. Thus, a survival analysis was performed to determine the time interval from presentation to clinical resolution of SRF. Secondary outcomes consisted of eyes with persistent SRF and factors affecting the therapeutic response. RESULTS: The mean 24-hour urinary free cortisol (UFC) levels were elevated at 181 ± 70 and 150 ± 68 µg/day (range: 20–150) in the treatment and control groups, respectively (p = 0.21). After controlling for age and gender, baseline UFC levels were significantly associated with choroidal thickness in both eyes (p < 0.05). Ketoconazole significantly increased the CSCR resolution with the median time to resolution of 7 vs 16 weeks (p < 0.01) and decreased the proportion of eyes receiving rescue therapy at 12 weeks (23.8% vs 50%; p = 0.01). Prolonged CSCR durations were likely found in elderly patients with thick choroids in fellow eyes. CONCLUSION: Patients with CSCR showed elevated glucocorticoids, which further correlated with their choroidal thickness. Using cortisol blockers may shorten the duration of existing SRF. Dove 2022-06-09 /pmc/articles/PMC9192783/ /pubmed/35711967 http://dx.doi.org/10.2147/OPTH.S368427 Text en © 2022 Chantarasorn et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Chantarasorn, Yodpong
Rasmidatta, Kochapong
Pokawattana, Itsara
Silpa-archa, Sukhum
Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy
title Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy
title_full Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy
title_fullStr Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy
title_full_unstemmed Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy
title_short Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy
title_sort effects of ketoconazole on the clinical recovery in central serous chorioretinopathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192783/
https://www.ncbi.nlm.nih.gov/pubmed/35711967
http://dx.doi.org/10.2147/OPTH.S368427
work_keys_str_mv AT chantarasornyodpong effectsofketoconazoleontheclinicalrecoveryincentralserouschorioretinopathy
AT rasmidattakochapong effectsofketoconazoleontheclinicalrecoveryincentralserouschorioretinopathy
AT pokawattanaitsara effectsofketoconazoleontheclinicalrecoveryincentralserouschorioretinopathy
AT silpaarchasukhum effectsofketoconazoleontheclinicalrecoveryincentralserouschorioretinopathy